StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals CRISPR Therapeutics Collaboration by Year

CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals CRISPR Therapeutics Collaboration: $62.2M in FY2025, up 96.8% from a year earlier.

Latest, FY2025
62.2
Period ended Dec 31, 2025
Change on a year earlier
+96.8%
31.6 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) ($M)Year on yearSource
FY2025Dec 31, 202562.2+96.8%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 202431.6-48.9%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 202361.9+103.0%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 202230.5-71.8%Form 10-K (filed 2025-02-13) ↗
FY2021Dec 31, 2021108+6.9%Form 10-K (filed 2024-02-15) ↗
FY2020Dec 31, 2020101–Form 10-K (filed 2023-02-10) ↗

Breakdown

What makes up CRISPR Therapeutics Collaboration

Cite this data

StockData. (2026). Vertex Pharmaceuticals CRISPR Therapeutics Collaboration ($M), annual FY2020–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-rd

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.